痛风患者非布司他与别嘌醇长期心血管安全性的比较(FAST):一项多中心、前瞻性、随机、开放标签、非劣效性试验
FAST研究是在英国、丹麦和瑞典开展的多中心、前瞻性、随机、开放标签、盲法终点、非劣效性试验,纳入6128例≥60岁、已接受别嘌醇且至少有一项额外心血管危险因素的痛风患者。经别嘌醇剂量优化使血尿酸<0.357 mmol/L(<6 mg/dL)后,随机继续优化剂量别嘌醇或起始非布司他80 mg/日、必要时增至120 mg/日以达到目标血尿酸。主要终点为因非致死性心肌梗死或生物标志物阳性急性冠脉综合征住院、非致死性卒中或心血管死亡的复合终点。治疗中分析显示非布司他组172例(1.72事件/100患者年) vs 别嘌醇组241例(2.05事件/100患者年),调整HR 0.85(95%CI 0.70-1.03),p<0.0001,达到非劣效(HR上限1.3)。结论为非布司他对主要心血管终点不劣于别嘌醇,长期使用与死亡或严重不良事件风险增加无关。
要点
- 非布司他对主要心血管复合终点不劣于别嘌醇:调整HR 0.85(95%CI 0.70-1.03),非劣效界值HR上限1.3,p<0.0001。
- 治疗中主要终点事件率:非布司他组172例(1.72事件/100患者年) vs 别嘌醇组241例(2.05事件/100患者年)。
- 死亡:非布司他组222/3063例(7.2%) vs 别嘌醇组263/3065例(8.6%);严重不良事件:非布司他组1720/3001例(57.3%) vs 别嘌醇组1812/3050例(59.4%)。
- 与治疗相关的严重不良事件:非布司他组19例(0.6%)共23起 vs 别嘌醇组5例(0.2%)共5起。
- 随机治疗停药:非布司他组973例(32.4%) vs 别嘌醇组503例(16.5%)。
适用人群与场景
- 纳入:英国、丹麦和瑞典的痛风患者,年龄≥60岁,已接受别嘌醇治疗,且至少有一项额外心血管危险因素。
- 排除:过去6个月内发生心肌梗死或卒中者,或患有严重充血性心力衰竭或严重肾损害者。
- 随机分组按既往心血管事件进行分层;共2046例(33.4%)有既往心血管疾病。
诊断标准与关键阈值
- 主要终点为复合终点:因非致死性心肌梗死或生物标志物阳性急性冠状动脉综合征住院、非致死性卒中或心血管死亡。
- 非劣效界值为Cox比例风险模型调整后的HR上限1.3。
- 血尿酸治疗目标为<0.357 mmol/L(<6 mg/dL)。
处置流程与药物剂量
- 导入期:所有患者别嘌醇剂量优化以达到血清尿酸<0.357 mmol/L(<6 mg/dL)。
- 随机后别嘌醇组继续使用优化剂量;非布司他组起始80 mg/日,必要时增至120 mg/日以达到目标血清尿酸浓度。
- 主要分析为治疗中分析,采用Cox比例风险模型(调整分层变量和国家)评估非布司他 vs 别嘌醇的HR。
研究设计与关键结果
- 研究类型:多中心、前瞻性、随机、开放标签、盲法终点、非劣效性试验;地点为英国、丹麦和瑞典。
- 样本量:6128例患者随机分配至别嘌醇组(n=3065)或非布司他组(n=3063);平均年龄71.0岁(SD 6.4),5225例(85.3%)男性,903例(14.7%)女性。
- 入组时间2011年12月20日至2018年1月26日;研究结束日期2019年12月31日;中位随访1467天(IQR 1029-2052),中位治疗中随访1324天(IQR 870-1919)。
- 失访:非布司他组189例(6.2%) vs 别嘌醇组169例(5.5%)退出所有随访。
- 主要终点(治疗中分析):非布司他组172例(1.72事件/100患者年) vs 别嘌醇组241例(2.05事件/100患者年),调整HR 0.85(95%CI 0.70-1.03),p<0.0001,达到非劣效。
- 死亡:非布司他组222/3063例(7.2%) vs 别嘌醇组263/3065例(8.6%)。
- 严重不良事件:非布司他组1720/3001例(57.3%) vs 别嘌醇组1812/3050例(59.4%)至少发生一次;与治疗相关的严重不良事件分别为非布司他组19例(0.6%)共23起 vs 别嘌醇组5例(0.2%)共5起。
- 随机治疗停药:非布司他组973例(32.4%) vs 别嘌醇组503例(16.5%)。
证据类型、等级与局限
- 证据类型:多中心、前瞻性、随机、开放标签、盲法终点、非劣效性试验。
- 非劣效界值HR上限1.3;主要终点调整HR 0.85(95%CI 0.70-1.03),p<0.0001,达到非劣效。
对床旁实践的改变
- 在≥60岁、已用别嘌醇且有额外心血管危险因素的痛风患者中,非布司他长期使用对主要心血管复合终点不劣于别嘌醇,且与死亡或严重不良事件风险增加无关。
- 非布司他组随机治疗停药比例(32.4%)高于别嘌醇组(16.5%),床旁需注意治疗持续性。
- 作者结论:非布司他对主要心血管终点不劣于别嘌醇,长期使用与死亡或严重不良事件风险增加无关。
指南或共识出处
- FAST试验,发表于Lancet;EU Clinical Trials Register(EudraCT 2011-001883-23)和ISRCTN(ISRCTN72443728)注册。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safety of febuxostat compared with allopurinol.
METHODS: We did a prospective, randomised, open-label, blinded-endpoint, non-inferiority trial of febuxostat versus allopurinol in patients with gout in the UK, Denmark, and Sweden. Eligible patients were 60 years or older, already receiving allopurinol, and had at least one additional cardiovascular risk factor. Those who had myocardial infarction or stroke in the previous 6 months or who had severe congestive heart failure or severe renal impairment were excluded. After a lead-in phase in which allopurinol dose was optimised towards achieving a serum urate concentration of less than 0·357 mmol/L (<6 mg/dL), patients were randomly assigned (1:1, with stratification according to previous cardiovascular events) to continue allopurinol (at the optimised dose) or start febuxostat at 80 mg/day, increasing to 120 mg/day if necessary to achieve the target serum urate concentration. The primary outcome was a composite of hospitalisation for non-fatal myocardial infarction or biomarker-positive acute coronary syndrome; non-fatal stroke; or cardiovascular death. The hazard ratio (HR) for febuxostat versus allopurinol in a Cox proportional hazards model (adjusted for the stratification variable and country) was assessed for non-inferiority (HR limit 1·3) in an on-treatment analysis. This study is registered with the EU Clinical Trials Register (EudraCT 2011-001883-23) and ISRCTN (ISRCTN72443728) and is now closed.
FINDINGS: From Dec 20, 2011, to Jan 26, 2018, 6128 patients (mean age 71·0 years [SD 6·4], 5225 [85·3%] men, 903 [14·7%] women, 2046 [33·4%] with previous cardiovascular disease) were enrolled and randomly allocated to receive allopurinol (n=3065) or febuxostat (n=3063). By the study end date (Dec 31, 2019), 189 (6·2%) patients in the febuxostat group and 169 (5·5%) in the allopurinol group withdrew from all follow-up. Median follow-up time was 1467 days (IQR 1029-2052) and median on-treatment follow-up was 1324 days (IQR 870-1919). For incidence of the primary endpoint, on-treatment, febuxostat (172 patients [1·72 events per 100 patient-years]) was non-inferior to allopurinol (241 patients [2·05 events per 100 patient-years]; adjusted HR 0·85 [95% CI 0·70-1·03], p<0·0001). In the febuxostat group, 222 (7·2%) of 3063 patients died and 1720 (57·3%) of 3001 in the safety analysis set had at least one serious adverse event (with 23 events in 19 [0·6%] patients related to treatment). In the allopurinol group, 263 (8·6%) of 3065 patients died and 1812 (59·4%) of 3050 had one or more serious adverse events (with five events in five [0·2%] patients related to treatment). Randomised therapy was discontinued in 973 (32·4%) patients in the febuxostat group and 503 (16·5%) patients in the allopurinol group.
INTERPRETATION: Febuxostat is non-inferior to allopurinol therapy with respect to the primary cardiovascular endpoint, and its long-term use is not associated with an increased risk of death or serious adverse events compared with allopurinol.
FUNDING: Menarini, Ipsen, and Teijin Pharma Ltd.
参考来源
- Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020. PMID: 33181081. doi:10.1016/S0140-6736(20)32234-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。